Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0GV5G
|
|||
| Drug Name |
PMID25666693-Compound-66
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cancer related pain [ICD-11: MG30; ICD-10: R52.1, R52.2] | Patented | [1] | |
| Inflammatory pain [ICD-11: MG30.42; ICD-10: R52, G89] | Patented | [1] | ||
| Neuropathic pain [ICD-11: 8E43.0] | Patented | [1] | ||
| Osteoarthritis pain [ICD-11: MG30.31] | Patented | [1] | ||
| Company |
Japan Tobacco, Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H27F2N3O4
|
|||
| Canonical SMILES |
CC1=CN=C(C=C1)N2C(COC3=C(C=CC=C32)C(=O)NC4=CC(=C(C(=C4)F)OC(C)(C)C)F)CO
|
|||
| InChI |
1S/C26H27F2N3O4/c1-15-8-9-22(29-12-15)31-17(13-32)14-34-23-18(6-5-7-21(23)31)25(33)30-16-10-19(27)24(20(28)11-16)35-26(2,3)4/h5-12,17,32H,13-14H2,1-4H3,(H,30,33)/t17-/m0/s1
|
|||
| InChIKey |
XZRDDTOOBFNFRB-KRWDZBQOSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Transient receptor potential cation channel V1 (TRPV1) | Target Info | Antagonist | [1] |
| Target's Patent Info | Transient receptor potential cation channel V1 (TRPV1) | Target's Patent Info | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Inflammatory mediator regulation of TRP channels | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | Trk receptor signaling mediated by the MAPK pathway | |||
| Trk receptor signaling mediated by PI3K and PLC-gamma | ||||
| Reactome | TRP channels | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.